CoChat

Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials

Open access
Orme, Michelle, Nguyen, Hiep, Lu, Jackie, Thomas, Susan · 2017 · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Cited by 27

The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.

Abstract

Background: Clinical studies of patients with type 2 diabetes show that GLP-1 receptor agonists (GLP-1 RAs) improve glycemic control and promote weight loss. We conducted a Bayesian network meta-analysis (NMA) of placebo- and active-controlled randomized trials to assess the comparative effectiveness of liraglutide, albiglutide, dulaglutide, and exenatide twice daily and once weekly, with a focus on glycemic control. Materials and methods: We searched Medline, Embase, and the Cochrane Library (up to December 2014) for core registration programs for US-approved GLP-1 RAs. Patients reaching an A 1C target of <7% were analyzed with a binomial model and change in A 1C from baseline with a normal model. A covariate analysis assessed the impact of baseline A 1C and treatment background on outcomes. Results: The base-case NMA used 23 trials reporting A 1C outcomes at ~6 month follow-up. The results, unadjusted and adjusted for baseline A 1C , indicated that all GLP-1 RAs resulted in statistically significantly lower A 1C at follow-up compared with placebo. The odds of reaching the <7% target were also significantly better compared with placebo. With dulaglutide, exenatide once weekly, and liraglutide, the absolute reduction in A 1C at 6 months was 0.9%–1.4%, and was significantly better than exenatide twice daily. Albiglutide was not significantly different from exenatide twice daily. We estimate that ~50% of patients will meet the <7% A 1C target within 6 months of commencing GLP-1 RAs. Conclusion: This was a comprehensive assessment of the comparative effectiveness of GLP-1 RAs and A 1C outcome. GLP-1 RAs are a viable addition to oral antidiabetes therapy, and dulaglutide, exenatide once weekly, and liraglutide are the most effective. Keywords: type 2 diabetes, glucagon-like peptide-1-receptor agonists, GLP-1 RAs, network meta-analysis, comparative effectiveness

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dmso.s116810

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 23 references

Cited by

See all 27

Metadata

Authors
Orme, M., Nguyen, H., Lu, J., & Thomas, S.
Venue
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Published
2017-03
Volume
Volume 10
Pages
111-122
ISSN
1178-7007 (ISSN-L)
OpenAlex
W2604152120
Cited by
27
References
23
FWCI
0.84
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials. https://app.cochat.ai/papers/10.2147/dmso.s116810
The paper
Orme, M., Nguyen, H., Lu, J., & Thomas, S. (2017). Comparative effectiveness of glycemic control in patients with type 2 diabetes treated with GLP-1 receptor agonists: a network meta-analysis of placebo-controlled and active-comparator trials. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy. https://doi.org/10.2147/dmso.s116810

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.